The estimated Net Worth of Shu Chih Chen is at least $7.04 Milion dollars as of 9 March 2016. Shu Chen owns over 15,000 units of Atossa Therapeutics Inc stock worth over $6,609,439 and over the last 12 years he sold ATOS stock worth over $41,120. In addition, he makes $386,737 as Director at Atossa Therapeutics Inc.
Sign up
Shu Chen ATOS stock SEC Form 4 insiders trading
Shu has made over 4 trades of the Atossa Therapeutics Inc stock since 2013, according to the Form 4 filled with the SEC. Most recently he bought 15,000 units of ATOS stock worth $5,550 on 9 March 2016.
The largest trade he's ever made was buying 50,000 units of Atossa Therapeutics Inc stock on 19 January 2016 worth over $10,000. On average, Shu trades about 5,454 units every 56 days since 2013. As of 9 March 2016 he still owns at least 4,348,315 units of Atossa Therapeutics Inc stock.
You can see the complete history of Shu Chen stock trades at the bottom of the page.
Wallmine is a radically better financial terminal.
Sign up in seconds, it's free!
Wallmine is a radically better financial terminal.
Sign up in seconds, it's free!
Shu-Chih Chen biography
Dr. Shu-Chih Chen Ph.D. serves as Director of the Company. She was a founder of the Company and served as Chief Scientific Officer of the Company since it was incorporated in April 2009 through August 2014. She was an Associate Professor at National Yang Ming University, Taipei, Taiwan, and served as the principal investigator of an NIH RO1 grant studying tumor suppression by gap junction protein connexin 43 at the Department of Molecular Medicine at Northwest Hospital, Seattle, WA. She has two issued U.S. patents and 20 pending U.S. patent applications related to cancer therapeutics. Dr. Chen received her Ph.D. degree in microbiology and public health from Michigan State University in 1992 and has published extensively on molecular oncology. She received her B.S. degree in medical technology from National Yang Ming University, Taipei, Taiwan in 1984. Dr. Chen was selected to serve on the Company’s Board of Directors because of her role as a founder of the Company and her qualifications in medical technology and as a professor and researcher in the field of cancer therapeutics.
What is the salary of Shu Chen?
As the Director of Atossa Therapeutics Inc, the total compensation of Shu Chen at Atossa Therapeutics Inc is $386,737. There are 4 executives at Atossa Therapeutics Inc getting paid more, with Steven Quay having the highest compensation of $5,807,920.
How old is Shu Chen?
Shu Chen is 58, he's been the Director of Atossa Therapeutics Inc since 2014. There are 6 older and 2 younger executives at Atossa Therapeutics Inc. The oldest executive at Atossa Therapeutics Inc is Stephen Galli, 73, who is the Independent Director.
What's Shu Chen's mailing address?
Shu's mailing address filed with the SEC is C/O ATOSSA THERAPEUTICS, INC.,, 107 SPRING STREET, SEATTLE, WA, 98104.
Insiders trading at Atossa Therapeutics Inc
Over the last 12 years, insiders at Atossa Therapeutics Inc have traded over $114,740 worth of Atossa Therapeutics Inc stock and bought 274,300 units worth $204,285 . The most active insiders traders include Gregory L Weaver, Steven C Quay oraz Shu Chih Chen. On average, Atossa Therapeutics Inc executives and independent directors trade stock every 205 days with the average trade being worth of $38,260. The most recent stock trade was executed by Jonathan Finn on 10 April 2024, trading 25,000 units of ATOS stock currently worth $44,250.
What does Atossa Therapeutics Inc do?
atossa therapeutics, inc. develops and markets medical devices, laboratory tests, and therapeutics to address breast health conditions in the united states. the company's lead program is the development of endoxifen, an active metabolite of tamoxifen which is in phase ii studies to treat and prevent breast cancer. it is also developing intraductal microcatheter technology to target the delivery of therapies, including fulvestrant, immunotherapies, and chimeric antigen receptor t-cell therapies, directly to the site of breast cancer. the company was formerly known as atossa genetics inc. and changed its name to atossa therapeutics, inc. in january 2020. atossa therapeutics, inc. was founded in 2009 and is headquartered in seattle, washington.
What does Atossa Therapeutics Inc's logo look like?
Complete history of Shu Chen stock trades at Atossa Therapeutics Inc
Atossa Therapeutics Inc executives and stock owners
Atossa Therapeutics Inc executives and other stock owners filed with the SEC include:
-
Steven Quay,
Chairman of the Board, President, Chief Executive Officer -
Kyle Guse,
Chief Financial Officer, General Counsel, Secretary -
Dr. Steven C. Quay,
Chairman, CEO & Pres -
Kyle Guse CPA, Esq., CPA,
CFO, Gen. Counsel & Sec. -
Shu-Chih Chen,
Director -
Gregory Weaver,
Independent Director -
Scott Gordon,
IR Contact Officer -
Richard Steinhart,
Independent Director -
H. Lawrence Remmel,
Independent Director -
Stephen Galli,
Independent Director -
Janet Rose Rea MSPH, RAC,
Sr. VP of Regulatory, Quality & Clinical Affairs -
Delly Behen P.H.R.,
VP of Admin. & HR -
Heather Rees,
VP of Fin. & Accounting -
Janet Rose Rea,
Sr. VP of Regulatory, Quality & Clinical Affairs -
Scott Youmans,
Chief Operating Officer -
Heather Rees,
SVP, Finance and Accounting -
Jonathan Finn,
-
Tessa Cigler,
-
Christopher S. Destro,
Sr. VP, Sales and Marketing -
John Barnhart,
Director -
John E Sawyer,
See Remarks -
Peter J. Carbonaro,
Sr. Vice President, Operations -
Ben R Chen,
Sr. VP of Glob. Reg. Affairs -
Alexander D Cross,
Director